Wiener Medizinische Wochenschrift

, Volume 158, Issue 3–4, pp 110–115 | Cite as

Lifestyle-Medikamente in der Medizin

  • Wolfgang Harth
  • Kurt Seikowski
  • Barbara Hermes
  • Uwe Gieler
Übersicht
  • 202 Downloads

Zusammenfassung

Lifestyle-Medikamente sind eine wichtige neue Substanzgruppe, die von Gesunden eingenommen werden, um das individuelle Wohlbefinden und die Lebensqualität zu verbessern. Nootropika, Psychopharmaka, Hormone und sogenannte "Ecodrugs" zählen heute zu den Hauptgruppen. Meist steht der Wunsch nach ewiger Jugend, Schönheit sowie Potenz im Zentrum der Nachfrage, und Lifestyle-Medikamente werden eingenommen, um Befunde zu beeinflussen, denen natürliche Alterungsprozesse zugrunde liegen. Auch bei scheinbar harmlosen Lifestyle-Medikamenten muss der Arzt einen möglichen Missbrauch, deren Nebenwirkungen, Risiken und Komplikationen beachten. Weiterhin werden Lifestyle-Medikamente häufig von Patienten mit emotionalen Störungen besonders somatoformen Störungen eingenommen. Die Medikalisierung von physiologischen Lebensfunktionen soll dann – jedoch ohne Erfolg – psychosoziale Probleme lösen. Die Verwendung von Lifestyle-Medikamenten bei somatoformen Störungen ist kontraindiziert und eine Psychotherapie oder psychopharmakologische Behandlung steht im Vordergrund der Behandlungskonzeption. Der Artikel gibt eine Übersicht über den aktuellen Stand neuer Lifestyle-Medikamente.

Schlüsselwörter

Lifestyle-Medikamente Somatoforme Störung Körperdysmorphe Störung 

Lifestyle drugs in medicine

Summary

Lifestyle drugs have become an important new group of medications, which are taken by healthy people to increase the individual well-being and quality of life. Nootropics, psychopharmaceuticals, hormones and "ecodrugs" are today the main groups. The wish for eternal youth, beauty and potency is central, and lifestyle medications are also requested to influence cosmetic findings, which are usually simply a result of the natural aging process. Lifestyle drugs seem to be harmless, but the physician must pay attention to possible abuse, side effects, risks and complications. Additionally, however, lifestyle drugs are also frequently used by patients suffering from emotional disorders such as somatoform disorders. Medicalization of physiological life is then expected to solve psychosocial problems, but without success. The use of lifestyle medications in somatoform disorders is contraindicated and psychotherapy or psychopharmacological treatment come first. With this overview article, we would like to make an update of new lifestyle drugs.

Keywords

Lifestyle drugs Somatoform disorder Body dysmorphic disorder 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Coons SJ, Motheral BR (2000) Quality-of-Life drugs? Clin Ther 22: 773–774PubMedCrossRefGoogle Scholar
  2. Harth W, Gieler U (2006) Psychosomatische Dermatologie. Springer, Berlin Heidelberg New YorkGoogle Scholar
  3. Phillips KA (2006) An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 21: 177–179PubMedCrossRefGoogle Scholar
  4. Gilbert D, Walley T, New B (2000) Lifestyle medicines. BMJ 321: 1341–1344PubMedCrossRefGoogle Scholar
  5. Harth W, Linse R (2001) Body dysmorphic disorder and life-style drugs. Overview and case report with finasteride. Int J Clin Pharmacol Ther 39: 284–287PubMedGoogle Scholar
  6. Hesselink JM: Surfen mit Nebenwirkungen (1999) Probleme rund um die Smartdrugs. Dtsch Med Wochenschr 124: 707–710PubMedGoogle Scholar
  7. Hengeveld MW (1998) Somatization of erectile disorders by the introduction of sildenafil. Ned Tijdschr Geneeskd 142: 2333–2336PubMedGoogle Scholar
  8. Mbongue TB, Sommet A, Pathak A, Montastruc JL (2005) "Medicamentation" of society, non-diseases and non-medications: a point of view from social pharmacology. Eur J Clin Pharmacol 61: 309–313PubMedCrossRefGoogle Scholar
  9. Bella AJ, Brant WO, Lue TF, Brock GB (2006) Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 13: 3233–3238PubMedGoogle Scholar
  10. Claret L, Cox EH, McFadyen L, Pidgen A, Johnson PJ, Haughie S, Boolell M, Bruno R (2006) Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). Pharm Res 23: 1756–1764PubMedCrossRefGoogle Scholar
  11. Porst H, Behre HM, Jungwirth A, Burkart M (2007) Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction – an open, randomized cross-over study with flexible dosing. Eur J Med Res 26: 61–67Google Scholar
  12. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M (2006) Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male 9: 221–227Google Scholar
  13. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S (2005) Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90: 5226–5233PubMedCrossRefGoogle Scholar
  14. Seftel A (2005) Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. J Urol 173: 1279–1280Google Scholar
  15. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R (2006) An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 3: 628–638PubMedCrossRefGoogle Scholar
  16. Van der Lely AJ (2003) Hormone use and abuse: what is the difference between hormones as fountain of youth and doping in sports? J Endocrinol Invest 26: 932–936PubMedGoogle Scholar
  17. Bozzola E, Giacchero R, Barberi S, Borroni G (2004) Sutton's nevus and growth hormone therapy. Minerva Pediatr 56: 349–351PubMedGoogle Scholar
  18. Liebel FP, Zimmermann E (2006) L-diabetes-causes, pathogenesis and therapy. Med Hypotheses 67: 493–505PubMedCrossRefGoogle Scholar
  19. Burgmer M, Driesch G, Heuft G (2003) Das "Sisi syndrome": eine neue Depression? Nervenarzt 74: 440–444PubMedCrossRefGoogle Scholar
  20. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK (2005) Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 53: 253–262PubMedCrossRefGoogle Scholar
  21. Ashton H (2005) The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 18: 249–255PubMedCrossRefGoogle Scholar
  22. Halford JC, Blundell JE (2000) Pharmacology of appetite suppression. Prog Drug Res 54: 25–58PubMedGoogle Scholar
  23. Neuvonen PJ, Niemi M, Backman JT (2006) Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 80: 565–581PubMedCrossRefGoogle Scholar
  24. Pelissier-Alicot AL, Piercecchi-Marti MD, Bartoli C, Kuhlmann E, Coiffait PE, Sanvoisin A, Giocanti D, Leonetti G (2006) Abusive prescription of psychostimulants: a study of two cases. J Forensic Sci 51: 407–410PubMedCrossRefGoogle Scholar
  25. Knopman DS (2006) Current treatment of mild cognitive impairment and Alzheimer's disease. Curr Neurol Neurosci Rep 6: 365–371PubMedCrossRefGoogle Scholar
  26. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS (2006) The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 55: 1014–1023PubMedCrossRefGoogle Scholar
  27. Harth W, Linse R (2001) Botulinophilia: contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther 39: 460–463PubMedGoogle Scholar
  28. Hund M, Sinkgraven R, Rzany B (2004) Randomized, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methantheliniumbromide (Vagantin) in the treatment of focal hyperhidrosis. J Dtsch Dermatol Ges 2: 343–349PubMedCrossRefGoogle Scholar
  29. Darwin M, Schanzer S, Teichmann A, Blume-Peytavi U, Sterry W, Lademann J (2006) Functional food and bioavailability in the target organ skin. Hautarzt 57: 286–290PubMedCrossRefGoogle Scholar
  30. Schmidt JB (2000) Neue Aspekte der Prophylaxe und Therapie des Hautalterns. In Plettenberg A, Meigel WN, Moll I (Hrsg) Dermatologie an der Schwelle zum neuen Jahrtausend. Aktueller Stand von Klinik und Forschung. Springer, Berlin Heidelberg New YorkGoogle Scholar
  31. Geissler SE, Michelsen S, Plewig G (2003) Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 1: 952–958PubMedCrossRefGoogle Scholar
  32. Kadison R (2005) Getting an edge – use of stimulants and antidepressants in college. N Engl J Med 353: 1089–1091PubMedCrossRefGoogle Scholar
  33. Striegel H, Simon P, Frisch S, Roecker K, Dietz K, Dickhuth HH, Ulrich R (2006) Anabolic ergogenic substance users in fitness-sports: a distinct group supported by the health care system. Drug Alcohol Depend 81: 11–19PubMedCrossRefGoogle Scholar
  34. Gesellschaft für ästhetische Chirurgie Deutschland. Top 10 der Schönheitsoperationen. Pressemitteilung via Internet (10.3.2007). www.dgac.de
  35. Beck D (1977) Das Koryphäen-Killer-Syndrom. Dtsch Med Wochenschr 102: 303–307PubMedCrossRefGoogle Scholar
  36. Brosig B, Kupfer J, Niemeier V, Gieler U (2001) The Dorian Gray Syndrome: psychodynamic need for hair growth restorers and other fountains of youth. Int J Clin Pharmacol Ther 39: 279–283PubMedGoogle Scholar
  37. Stangier U, Gieler U (1997) Somatoforme Störungen in der Dermatologie. Psychotherapie 2: 91–101Google Scholar
  38. Gupta MA, Gupta AK (2006) Medically unexplained cutaneous sensory symptoms may represent somatoform dissociation: an empirical study. J Psychosom Res 60: 131–136PubMedCrossRefGoogle Scholar
  39. Glaser DA, Kaminer MS (2005) Body dysmorphic disorder and the liposuction patient. Dermatol Surg 31: 559–561PubMedCrossRefGoogle Scholar
  40. Driesch G, Burgmer M, Heuft G (2004) Körperdysmorphe Störung. Epidemiologie, klinische Symptomatik, Klassifikation und differenzielle Therapieindikationen. Nervenarzt 75: 917–929PubMedCrossRefGoogle Scholar
  41. Woodruff P, Higgins E, du Vivier A, Wessely S (1997) Psychiatric Illness in Patients referred to a Dermatology-Psychiatry Clinic. Gen Hosp Psychiatry 19: 29–35PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Wolfgang Harth
    • 1
  • Kurt Seikowski
    • 2
  • Barbara Hermes
    • 1
  • Uwe Gieler
    • 3
  1. 1.Klinik für Dermatologie und Phlebologie, Vivantes Klinikum Berlin FriedrichshainAkademisches Lehrkrankenhaus der Charité – Universitätsmedizin BerlinBerlinGermany
  2. 2.Klinik für Dermatologie, Venerologie und AllergologieUniversität LeipzigLeipzigGermany
  3. 3.Klinik für Psychosomatik und PsychotherapieJustus-Liebig-Universität GiessenGiessenGermany

Personalised recommendations